For the year ending 2025-12-31, ALNY had $690,155K increase in cash & cash equivalents over the period. $465,383K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 313,747 |
| Depreciation and amortization | 55,658 |
| Non-cash interest expense on liabilities related to the sale of future royalties and development funding | 238,399 |
| Stock-based compensation expense | 348,235 |
| Realized and unrealized loss on marketable equity securities | -2,306 |
| Loss related to convertible debt | -42,473 |
| Change in fair value of development derivative liability | 0 |
| Deferred income taxes | -2,198 |
| Other | -29,758 |
| Accounts receivable, net | 359,963 |
| Inventory | -8,474 |
| Prepaid expenses and other assets | 117,724 |
| Accounts payable, accrued expenses and other liabilities | 75,066 |
| Deferred revenue | -50,635 |
| Net cash provided by (used in) operating activities | 524,080 |
| Purchases of property, plant and equipment | 58,697 |
| Purchases of marketable securities | 1,305,081 |
| Sales and maturities of marketable securities | 1,802,257 |
| Proceeds from maturity of restricted investments | 59,775 |
| Purchases of restricted investments | 59,775 |
| Other investing activities | 2,150 |
| Net cash provided by (used in) investing activities | 436,329 |
| Proceeds from issuance of 0.00 convertible senior notes due 2028, net | 645,692 |
| Purchases of capped calls related to 0.00 convertible senior notes due 2028 | 35,311 |
| Repayment of 1.00 convertible senior notes due 2027 | 1,154,913 |
| Payment of issuance costs for revolving credit agreement | 2,414 |
| Proceeds from exercise of stock options and other types of equity, net | 250,028 |
| Proceeds from liabilities related to the sale of future royalties and development funding | 6,000 |
| Repayment of liabilities related to the sale of future royalties and development funding | 14,272 |
| (repayment of) proceeds from development derivative liability, net | 0 |
| Net cash (used in) provided by financing activities | -305,190 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 34,936 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 690,155 |
| Cash and cash equivalents at beginning of period | 968,652 |
| Cash and cash equivalents at end of period | 1,658,807 |
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
ALNYLAM PHARMACEUTICALS, INC. (ALNY)